Study MB12 versus Keytruda for newly diagnosed stage IV lung cancer
Treatments studied
Part of Cancer, Immune system & allergy, Lungs & breathing clinical trials.
This Phase 3 trial compares MB12 with Keytruda (both cancer medicines) for people with newly diagnosed stage IV non-squamous non-small-cell lung cancer. It looks at whether MB12 can work as well or better than Keytruda, and compares safety and immune responses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent before any study tests
- Have newly diagnosed stage IV non-squamous NSCLC with no prior whole-body (systemic) treatment for this cancer
- Have at least one measurable tumor spot on scans and meet the study’s PD-L1 test requirement (PD-L1 ≥50%)
- Be in good enough general health (ECOG 0 to 1) and expected to live at least 3 months
- Have blood, liver, kidney, thyroid, and clotting tests that are within allowed ranges
- Be able to avoid certain medicines and treatments during the study (especially immune checkpoint drugs and recent chemotherapy)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called pembrolizumab (Keytruda) in people with advanced non-small cell lung cancer who haven't received treatment for metastatic disease. Researchers will also study your T-cells (a type of immune cell) to see if they can predict how well the drug works.
This trial tests if a new drug, MB12, works as well as Keytruda for people with advanced non-small cell lung cancer who haven't had treatment yet. It aims to offer a more affordable option.
This trial tests if the immunotherapy drug pembrolizumab (Keytruda) can help people with advanced non-small cell lung cancer by boosting the body's own immune cells (T-cells) to fight the cancer. It's for people who have not had any prior cancer treatment.
This Phase 1/2 study tests pembrolizumab (an immune-based cancer treatment) either alone or with chemotherapy in people newly diagnosed with stage IV non-small cell lung cancer (NSCLC). It looks at how well the treatments work and whether they are safe, especially in people who haven’t had treatment yet for metastatic disease.
This trial tests a new drug, QL2107, combined with chemotherapy, compared to the standard drug Keytruda (pembrolizumab) with chemotherapy. It is for people with stage IV non-squamous non-small cell lung cancer that does not have certain gene mutations (EGFR or ALK).
This trial tests whether using two immunotherapy drugs together works better than a single drug for people with advanced non-small cell lung cancer that does not have the PD-L1 protein. The study aims to find a more effective treatment for this specific type of lung cancer.
Hear when a new Non Small Cell Lung Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.